MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM
出版年份 2019 全文链接
标题
MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM
作者
关键词
-
出版物
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume -, Issue -, Pages 201819085
出版商
Proceedings of the National Academy of Sciences
发表日期
2019-03-22
DOI
10.1073/pnas.1819085116
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification
- (2016) Jieyi Wang et al. BMC CANCER
- A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors
- (2016) Sheri L. Moores et al. CANCER RESEARCH
- A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
- (2016) Lee S. Rosen et al. CLINICAL CANCER RESEARCH
- MINI01.03: Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET+ NSCLC
- (2016) Todd M. Bauer et al. Journal of Thoracic Oncology
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
- (2016) I. Tirosh et al. SCIENCE
- Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
- (2016) M. Bahcall et al. Cancer Discovery
- 469PHighly selective c-Met inhibitor tepotinib plus gefitinib is active in Asian patients with c-Met+ NSCLC
- (2015) R. Soo et al. ANNALS OF ONCOLOGY
- Data2Dynamics: a modeling environment tailored to parameter estimation in dynamical systems: Fig. 1.
- (2015) A. Raue et al. BIOINFORMATICS
- cMet: Results in papillary renal cell carcinoma of a phase I study of AZD6094/volitinib leading to a phase 2 clinical trial with AZD6094/volitinib in patients with advanced papillary renal cell cancer (PRCC).
- (2015) Hui Kong Gan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Giorgio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- MET is required for the recruitment of anti-tumoural neutrophils
- (2015) Veronica Finisguerra et al. NATURE
- Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program
- (2015) Roland Morley et al. PLoS One
- Microenvironment-Derived HGF Overcomes Genetically Determined Sensitivity to Anti-MET Drugs
- (2014) S. Pennacchietti et al. CANCER RESEARCH
- LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
- (2014) L. Liu et al. CLINICAL CANCER RESEARCH
- Antiparallel Conformation of Knob and Hole Aglycosylated Half-Antibody Homodimers Is Mediated by a CH2–CH3 Hydrophobic Interaction
- (2014) J.Michael Elliott et al. JOURNAL OF MOLECULAR BIOLOGY
- Alternative Recognition of the Conserved Stem Epitope in Influenza A Virus Hemagglutinin by a VH3-30-Encoded Heterosubtypic Antibody
- (2014) A. Wyrzucki et al. JOURNAL OF VIROLOGY
- Crystal structure of deglycosylated human IgG4-Fc
- (2014) Anna M. Davies et al. MOLECULAR IMMUNOLOGY
- An allosteric switch for pro-HGF/Met signaling using zymogen activator peptides
- (2014) Kyle E Landgraf et al. Nature Chemical Biology
- Crystal structure and its bearing towards an understanding of key biological functions of EpCAM
- (2014) Miha Pavšič et al. Nature Communications
- Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
- (2013) R. Katayama et al. CANCER RESEARCH
- A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer
- (2013) Yoon-Koo Kang et al. INVESTIGATIONAL NEW DRUGS
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2013) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Structural Determinants of Unique Properties of Human IgG4-Fc
- (2013) Anna M. Davies et al. JOURNAL OF MOLECULAR BIOLOGY
- Rapid optimization and prototyping for therapeutic antibody-like molecules
- (2013) Lihui Xu et al. mAbs
- Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies
- (2013) Brian D. Harms et al. METHODS
- A Heterodimeric Fc-Based Bispecific Antibody Simultaneously Targeting VEGFR-2 and Met Exhibits Potent Antitumor Activity
- (2013) H.-J. Choi et al. MOLECULAR CANCER THERAPEUTICS
- Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
- (2013) M. Merchant et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
- (2013) Alberto Bardelli et al. Cancer Discovery
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
- (2011) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
- (2011) Jochen K. Lennerz et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer
- (2011) Francesca De Bacco et al. JNCI-Journal of the National Cancer Institute
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies
- (2010) Markus Münz et al. Cancer Cell International
- EpCAM in carcinogenesis: the good, the bad or the ugly
- (2010) B. T. F. van der Gun et al. CARCINOGENESIS
- Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody
- (2010) Giovanni Pacchiana et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer
- (2010) Heounjeong Go et al. Journal of Thoracic Oncology
- MET signalling: principles and functions in development, organ regeneration and cancer
- (2010) Livio Trusolino et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion
- (2010) K. D. Grugan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural characterization of a human Fc fragment engineered for lack of effector functions
- (2008) Vaheh Oganesyan et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases
- (2008) Zhao-Shi Zeng et al. CANCER LETTERS
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search